Ryan Rasmussen was determined to lose weight so he would be around to ski and spend time with his wife and children.

Companies like Hims & Hers and WeightWatchers have been providing ... approved, and studied Zepbound for patients who are being asked to pay out-of-pocket," he added. Jonsson also told Reuters ...

The shortage, which began in December 2022 for Mounjaro and extended to Zepbound in April 2023 ... with shares of Hims & Hers Health, a company offering compounded versions of GLP-1 treatments ...

Zepbound, which has the same active ingredient ... Keerthi Reddy, 32, who underwent bariatric surgery a few years back, took her first Mounjaro shot this week at Vennapusa's clinic.

But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, was particularly fraught. Days ...

Zepbound, which has the same active ingredient ... Keerthi Reddy, 32, who underwent bariatric surgery a few years back, took her first Mounjaro shot this week at Vennapusa's clinic. "My friends and ...

Millions of Americans are on their way to healthier weights. We’re following the big shifts in their lives. A 46-year-old dad tells how his life has changed. (Photo illustration: Yahoo News ...

Shares of weight-loss drugmakers Novo Nordisk A/S and Eli Lilly and Co. got a nice lift Monday, after a potential competitor decided to cancel development of its GLP-1 obesity drug. “We continue ...

That was music to the ears of investors in Novo Nordisk, which makes diabetes and obesity treatments Ozempic and Wegovy; and in Eli Lilly, which makes Mounjaro and Zepbound diabetes and obesity drugs.